About Our Current Research Studies
Our current studies and a brief description of each are listed below. More information about these studies, including eligibility criteria, funding sources, and team members involved can be found by clicking the study’s name.
Current Studies
Cravesupport: Measuring and Intervening Craving Moments in Substance Use Disorders (SUD) Using Bio-Behavioral Sensors
The CRAVE study aims to gather data from individuals struggling with opioid use disorder to explore the potential use of wearable devices in preventing instances of cravings in the future.
OARS 7: A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms
The purpose of this two-part study is to see if a drug called seltorexant (JNJ-42847922) added to your current antidepressant treatment would help to improve your depression and your sleep problems (such as difficulty falling asleep, staying asleep, waking up too early or otherwise poor-quality sleep).
AMPA -NOVA 1: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
The purpose of this 12 – 14 weeks study is to look at whether the study drug, NBI-1065845, works to improve depression symptoms when taken with your current antidepressants. You can take part in this study if you are currently on antidepressants that are not working well enough. The study drug will be compared with a placebo (which looks like the study drug but contains no active ingredients).
AMPA Vega 2: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
The purpose of this research study is to find out if the investigational study drug (NBI-1065845) is safe to be given for a longer period of time to those with depression. The study will last for 158 to 162 weeks.
A study to investigate the safety and efficacy of TMP-301 compared to placebo in adult patients with alcohol use disorder
The purpose of this research is to learn more about investigational study drug TMP 301 as a potential treatment for people with alcohol use disorder (AUD).
